Spotlight on strontium ranelate: in postmenopausal osteoporosis

Area of Science:

• Pharmacology
• Bone Biology
• Osteoporosis Treatment

Background:

• Postmenopausal osteoporosis is a significant health concern characterized by bone loss.
• Current treatments aim to reduce bone resorption or increase bone formation.

Purpose of the Study:

• To review the pharmacology, efficacy, and tolerability of strontium ranelate for postmenopausal osteoporosis.
• To evaluate its long-term effects on bone turnover and fracture risk.

Main Methods:

• Review of data from large, double-blind, placebo-controlled, multicentre trials (5 years) with a 3-year extension phase.
• Analysis of bone mineral density, bone turnover markers, and fracture incidence.

Main Results:

• Strontium ranelate increases bone formation and reduces resorption, rebalancing bone turnover.
• Significant reduction in vertebral and nonvertebral fractures over 8 years.
• Improvements in bone mineral density and bone turnover markers observed.

Conclusions:

• Strontium ranelate is an effective first-line treatment for postmenopausal osteoporosis.
• Generally well-tolerated with a manageable adverse event profile.
• Provides sustained fracture protection and improves bone health markers.